X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (513611) 513611
Newsletter (128133) 128133
Publication (34952) 34952
Newspaper Article (14288) 14288
Book Review (2576) 2576
Magazine Article (2199) 2199
Book Chapter (968) 968
Conference Proceeding (934) 934
Book / eBook (841) 841
Dissertation (491) 491
Transcript (460) 460
Web Resource (381) 381
Trade Publication Article (353) 353
Reference (171) 171
Government Document (104) 104
Streaming Video (94) 94
Data Set (56) 56
Paper (39) 39
Journal / eJournal (35) 35
Presentation (13) 13
Report (7) 7
Poster (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (416121) 416121
antineoplastic agents (215767) 215767
cancer (211541) 211541
antimitotic agents (198372) 198372
female (198354) 198354
index medicus (181697) 181697
male (163401) 163401
oncology (153900) 153900
middle aged (125823) 125823
care and treatment (125582) 125582
research (116084) 116084
animals (116026) 116026
antineoplastic agents - therapeutic use (106679) 106679
antineoplastic combined chemotherapy protocols - therapeutic use (104279) 104279
aged (103594) 103594
adult (102404) 102404
antineoplastic agents - pharmacology (97174) 97174
chemotherapy (93268) 93268
oncology, experimental (63945) 63945
cell line, tumor (63351) 63351
treatment outcome (63108) 63108
mice (62236) 62236
reports (51096) 51096
pharmacology & pharmacy (50146) 50146
health aspects (47114) 47114
apoptosis (47034) 47034
antineoplastic agents - administration & dosage (42234) 42234
analysis (41241) 41241
combined modality therapy (40697) 40697
prognosis (40241) 40241
antineoplastic agents - adverse effects (40014) 40014
neoplasms - drug therapy (39178) 39178
drug therapy (38376) 38376
universities and colleges (34972) 34972
breast neoplasms - drug therapy (33753) 33753
apoptosis - drug effects (33504) 33504
therapy (33410) 33410
breast cancer (33029) 33029
hematology (32175) 32175
antineoplastic agents - chemistry (32092) 32092
drugs (31935) 31935
aged, 80 and over (31538) 31538
dose-response relationship, drug (30765) 30765
antineoplastic combined chemotherapy protocols - adverse effects (30110) 30110
neoplasm staging (28880) 28880
tumors (28856) 28856
cell proliferation - drug effects (28132) 28132
adolescent (27940) 27940
retrospective studies (26706) 26706
biochemistry & molecular biology (26691) 26691
metastasis (26183) 26183
lung neoplasms - drug therapy (25632) 25632
expression (25623) 25623
chemistry, medicinal (24313) 24313
time factors (23721) 23721
carcinoma (23597) 23597
survival rate (23123) 23123
disease-free survival (22922) 22922
cell survival - drug effects (22523) 22523
tumor cells, cultured (22498) 22498
survival (22467) 22467
cisplatin - administration & dosage (22357) 22357
medicine & public health (22221) 22221
cisplatin (22014) 22014
radiotherapy (21908) 21908
child (21746) 21746
antineoplastic combined chemotherapy protocols - administration & dosage (21167) 21167
follow-up studies (20933) 20933
surgery (20692) 20692
genetic aspects (20581) 20581
survival analysis (19813) 19813
drug administration schedule (19759) 19759
rats (19566) 19566
drug screening assays, antitumor (19463) 19463
article (19190) 19190
doxorubicin - administration & dosage (18851) 18851
chemotherapy, adjuvant (18792) 18792
medical research (18436) 18436
pharmaceutical industry (18422) 18422
antineoplastic agents, phytogenic - pharmacology (18281) 18281
cells (18252) 18252
fluorouracil - administration & dosage (18167) 18167
breast neoplasms - pathology (18030) 18030
drug resistance, neoplasm (17475) 17475
antineoplastic agents - chemical synthesis (17277) 17277
in-vitro (16786) 16786
clinical trials as topic (16703) 16703
risk factors (16465) 16465
clinical trials (16405) 16405
hematology, oncology and palliative medicine (16183) 16183
structure-activity relationship (15974) 15974
cyclophosphamide - administration & dosage (15467) 15467
mice, nude (15309) 15309
molecular structure (14798) 14798
leukemia (14789) 14789
trial (14763) 14763
cell biology (14670) 14670
cytotoxicity (14575) 14575
remission induction (14472) 14472
neoplasm metastasis (14250) 14250
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (448) 448
Online Resources - Online (375) 375
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (55) 55
Collection Dvlpm't (Acquisitions) - Vendor file (47) 47
Collection Dvlpm't (Acquisitions) - Closed Orders (35) 35
UofT at Mississauga - Stacks (16) 16
Gerstein Science - Periodical Stacks (15) 15
Scarborough Hospital - Online (6) 6
Chemistry (A D Allen) - Stacks (5) 5
Scarborough Hospital - Birchmount (5) 5
Gerstein Science - Bindery (4) 4
Lakeridge Health Sciences - Online (4) 4
UTL at Downsview - May be requested (4) 4
Robarts - Stacks (3) 3
St. Michael's Hospital - Stacks (3) 3
Sunnybrook Health Sciences Centre - Sunnybrook Reference (3) 3
Credit Valley Hospital - Stacks (2) 2
Earth Sciences (Noranda) - Stacks (2) 2
East Asian (Cheng Yu Tung) - Reference (2) 2
Gerstein Science - Circulation Desk (2) 2
Gerstein Science - Reference (2) 2
Scarborough Hospital - General (2) 2
Sunnybrook Health Sciences Centre - Online (2) 2
Baycrest Hospital - Wellness Library (1) 1
Credit Valley Hospital - Special Collections (1) 1
Dentistry (Harry R Abbott) - Course Reserves (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Gerstein Science - Theses (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Sunnybrook Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
St. Michael's Hospital - Online (1) 1
St. Michael's Hospital - Pharmacy (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Missing (1) 1
Sunnybrook Health Sciences Centre - Oshawa (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Periodicals (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT Schools - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
Women's College Hospital - Online (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (605316) 605316
Japanese (16446) 16446
German (8163) 8163
French (7734) 7734
Chinese (7477) 7477
Russian (5122) 5122
Italian (2526) 2526
Spanish (2482) 2482
Polish (1542) 1542
Hungarian (723) 723
Czech (661) 661
Dutch (583) 583
Danish (383) 383
Portuguese (323) 323
Swedish (251) 251
Norwegian (226) 226
Ukrainian (181) 181
Romanian (172) 172
Hebrew (161) 161
Korean (155) 155
Finnish (139) 139
Bulgarian (125) 125
Croatian (111) 111
Serbian (111) 111
Slovak (84) 84
Turkish (50) 50
Lithuanian (29) 29
Bosnian (13) 13
Greek (7) 7
Afrikaans (3) 3
Slovenian (2) 2
Amharic (1) 1
Arabic (1) 1
Catalan (1) 1
Icelandic (1) 1
Kurdish (1) 1
Manx (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2009, Current clinical oncology, ISBN 9781603270861, xxviii, 637
A panel of international authorities analyzes in depth in this book the role of the lymphovascular system in the spread of cancer. They also summarize the... 
Neoplasms Invasiveness | Neoplasm Metastasis | Clinical & internal medicine | Metastasis | Lymphangiogenesis - drug effects | Pathology | Oncology | Medicine & Public Health | Radiotherapy | Surgical Oncology
Book
2007, ISBN 9780195187762, ix, 355
Book
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
The natural flavonoid fisetin was recently identified as a lead compound that stabilizes endothelial cell microtubules. In this study, we investigated the... 
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | APOPTOSIS | ANTIINFLAMMATORY ACTIVITY | ACTIVATION | CELL-CYCLE ARREST | PROLIFERATION | METASTATIC COLORECTAL-CANCER | IN-VITRO | ONCOLOGY | ENDOTHELIAL-CELLS | PHARMACOLOGY & PHARMACY | EA.hy 926 endothelial cells | INHIBITORS | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Antineoplastic agents | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Anti-cancer drug design, ISSN 0266-9536, 1985
Journal
Cancer chemotherapy and pharmacology, ISSN 0344-5704
Journal
2007, Cancer drug discovery and development, ISBN 1588296725, xiv, 455
This volume provides a biological and pharmacological background for regional cancer therapy, strategies and techniques for regional therapies, and specific... 
Clinical & internal medicine | Cancer | Surgical oncology | Cancer Research | Oncology | Biomedicine | Radiotherapy | Surgical Oncology | Surgery | Drug targeting | Antineoplastic agents | Infusion therapy
Book
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 10/2014, Volume 85, pp. 418 - 437
The 2′-deoxynucleoside 5′-phosphate -hydrolase 1 (DNPH1) has been proposed as a new molecular target for cancer treatment. Here, we describe the synthesis of a... 
Inhibitor | Cross-coupling reaction | DNPH1 | Nucleoside analogues | Crystal structure | Cancer | 5'-MONOPHOSPHATE N-GLYCOSIDASE | CHEMISTRY, MEDICINAL | CYTOSTATIC 6-ARYLPURINE NUCLEOSIDES | C-MYC | HL-60 CELLS | LEAVING GROUPS | 2'-DEOXYRIBONUCLEOSIDE 5'-MONOPHOSPHATE | ANTICANCER ACTIVITY | CROSS-COUPLING REACTIONS | PROTEIN-LIGAND COMPLEXES | HYDROLASE RCL | Purine Nucleotides - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Proto-Oncogene Proteins - chemistry | Structure-Activity Relationship | Enzyme Inhibitors - chemical synthesis | Molecular Targeted Therapy | Purine Nucleotides - chemistry | N-Glycosyl Hydrolases - chemistry | Purine Nucleotides - metabolism | Antineoplastic Agents - metabolism | Enzyme Inhibitors - chemistry | Drug Design | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Chemistry Techniques, Synthetic | Enzyme Inhibitors - metabolism | N-Glycosyl Hydrolases - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Rats | Nuclear Proteins - metabolism | Purine Nucleotides - chemical synthesis | Antineoplastic Agents - chemistry | Nuclear Proteins - chemistry | N-Glycosyl Hydrolases - metabolism | Animals | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Protein Conformation | Molecular Docking Simulation | Drug Screening Assays, Antitumor | Enzymes | Colon cancer | Leukemia | Crystals | Hydrolases | Nucleotides | Structure | Nuclear Proteins/chemistry | Purine Nucleotides/metabolism | Proto-Oncogene Proteins/antagonists & inhibitors | Enzyme Inhibitors/metabolism | Enzyme Inhibitors/pharmacology | Life Sciences | Antineoplastic Agents/pharmacology | N-Glycosyl Hydrolases/antagonists & inhibitors | Nuclear Proteins/antagonists & inhibitors | N-Glycosyl Hydrolases/metabolism | Nuclear Proteins/metabolism | Purine Nucleotides/chemistry | Enzyme Inhibitors/chemistry | Purine Nucleotides/chemical synthesis | Enzyme Inhibitors/chemical synthesis | Antineoplastic Agents/metabolism | N-Glycosyl Hydrolases/chemistry | Proto-Oncogene Proteins/chemistry | Biochemistry, Molecular Biology | Proto-Oncogene Proteins/metabolism | Purine Nucleotides/pharmacology | Antineoplastic Agents/chemistry | Antineoplastic Agents/chemical synthesis
Journal Article
Anti-cancer drugs, ISSN 0959-4973, 1990
Journal
2004, Cancer drug discovery and development., ISBN 9781592597345, xiv, 623
Book
2008, 1. Aufl., Cancer drug discovery and development series, ISBN 1934115290, xxi, 419
Book
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | PLUS DEXAMETHASONE | ABNORMALITIES | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | DELETION | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use
Journal Article
2011, Eighth Edition., ISBN 160831782X, xiv, 875
Skeel's Handbook of Cancer Chemotherapy combines in one place the most current rationale and specific details necessary to safely administer chemotherapy for... 
Antineoplastic Agents | drug therapy | administration & dosage | Neoplasms | Handbooks, manuals, etc | Chemotherapy | Cancer
Book
Biochemical Pharmacology, ISSN 0006-2952, 08/2014, Volume 90, Issue 3, pp. 212 - 225
This study was aimed at investigating the reversal effect of oroxylin A, a naturally bioactive monoflavonoid separated and purified from , in human chronic... 
PI3K/Akt/NF-κB pathway | Oroxylin A | CXCL12/CXCR4 axis | K562/ADM | Reversal effect | PI3K/Akt/NF-kappa B pathway | DOUBLING TIME | MARROW | MEDIATED MULTIDRUG-RESISTANCE | DOWN-REGULATION | CXCR4 | CXCL12/OCCR4 axis | MESENCHYMAL STROMAL CELLS | IN-VITRO | CANCER DEVELOPMENT | CHRONIC LYMPHOCYTIC-LEUKEMIA | PHARMACOLOGY & PHARMACY | NF-KAPPA-B | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antibiotics, Antineoplastic - pharmacology | Apoptosis - drug effects | Humans | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Proteins - antagonists & inhibitors | Flavonoids - adverse effects | Neoplasm Proteins - metabolism | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Antineoplastic Agents, Phytogenic - administration & dosage | RNA Interference | Female | Receptors, CXCR4 - genetics | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Neoplasm Proteins - genetics | Leukemia, Myeloid, Chronic-Phase - metabolism | Phosphatidylinositol 3-Kinase - metabolism | Antineoplastic Agents, Phytogenic - adverse effects | Doxorubicin - administration & dosage | Receptors, CXCR4 - antagonists & inhibitors | Leukemia, Myeloid, Chronic-Phase - drug therapy | Random Allocation | Receptors, CXCR4 - metabolism | Antibiotics, Antineoplastic - administration & dosage | Phosphatidylinositol 3-Kinase - chemistry | Xenograft Model Antitumor Assays | Animals | Chemokine CXCL12 - metabolism | Antibiotics, Antineoplastic - therapeutic use | Neoplasm Proteins - agonists | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Cell Line, Tumor | Receptors, CXCR4 - agonists | Mice | Antineoplastic Agents, Phytogenic - pharmacology | Doxorubicin - adverse effects | Doxorubicin - pharmacology | Drug Resistance, Neoplasm - drug effects | Anthracyclines | Index Medicus
Journal Article
2008, ISBN 9780123694485, xv, 473 p., [27] p. of plates
The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes... 
Antineoplastic agents | Clinical & internal medicine | Design | Development
Book